Peapack Gladstone Financial Corp Halozyme Therapeutics, Inc. Transaction History
Peapack Gladstone Financial Corp
- $6.74 Billion
- Q1 2025
A detailed history of Peapack Gladstone Financial Corp transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Peapack Gladstone Financial Corp holds 11,550 shares of HALO stock, worth $666,781. This represents 0.01% of its overall portfolio holdings.
Number of Shares
11,550
Previous 7,550
52.98%
Holding current value
$666,781
Previous $361,000
104.16%
% of portfolio
0.01%
Previous 0.01%
Shares
11 transactions
Others Institutions Holding HALO
# of Institutions
589Shares Held
122MCall Options Held
308KPut Options Held
131K-
Black Rock Inc. New York, NY17.6MShares$1.02 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.8MShares$741 Million0.02% of portfolio
-
State Street Corp Boston, MA6.05MShares$349 Million0.02% of portfolio
-
Invesco Ltd. Atlanta, GA3.89MShares$225 Million0.05% of portfolio
-
Snyder Capital Management L P San Francisco, CA3.67MShares$212 Million5.31% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $8.04B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...